External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.

Naree Warnnissorn,Nonglak Kanitsap,Pimjai Niparuck,Paisarn Boonsakan,Prapasri Kulalert,Wasithep Limvorapitak,Lantarima Bhoopat,Supawee Saengboon,Pichika Chantrathammachart,Teeraya Puavilai,Suporn Chuncharunee

HEMATOLOGY（2022）

引用 3|浏览10

暂无评分

摘要

NCCN-IPI is the best prognostic index compared to IPI and R-IPI in prior studies. However, the prognostic model for DLBCL patients treated with R-CHOP requires updating or integrating biomarkers to improve discrimination to the acceptable level (c-index 0.7).

查看译文

关键词

Diffuse large B-cell lymphoma,R-CHOP,comparison,enhanced-international prognostic index,external validation,international prognostic index,progression-free survival,revised-international prognostic index

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要